LeonaBio, Inc.LONA
Oncology8 cited findings · profile updated 2026-08-20
7.83 USDnot live — refreshed daily
About LeonaBio, Inc.
LeonaBio, Inc. (LONA) is an oncology research site with ongoing clinical development. The ELAINE-1 trial reported a median progression-free survival of 5.6 months, compared to 3.7 months for the comparator. In the same trial, the objective response rate was 13.3%, versus 2.9% for the comparator. The ELAINE-2 trial demonstrated a median progression-free survival of 13 months, an objective response rate of 56%, and a clinical benefit rate of 65.5%. A Phase 3 trial, ELAINE-3, is also underway.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Median progression-free survival (ELAINE-1) | 5.6 months (comparator: 3.7 months) | LeonaBio, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Objective response rate (ELAINE-1) | 13.3 % (comparator: 2.9 %) | LeonaBio, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Median progression-free survival (ELAINE-2) | 13 months | LeonaBio, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Objective response rate (ELAINE-2) | 56 % | LeonaBio, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Clinical benefit rate (ELAINE-2) | 65.5 % | LeonaBio, Inc. — SEC 8-K (2026-08-14), p.p.2 |
| Trial phase (ELAINE-3) | Phase 3 | LeonaBio, Inc. — SEC 8-K (2026-08-14), p.p.2 |
Key projects
- ELAINE-1
The ELAINE-1 trial reported a median progression-free survival of 5.6 months, compared to 3.7 months for the comparator.
- ELAINE-2
The ELAINE-2 trial demonstrated a median progression-free survival of 13 months.
- ELAINE-3
ELAINE-3 is a Phase 3 trial.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →